vs

Side-by-side financial comparison of Cheer Holding, Inc. (CHR) and GeneDx Holdings Corp. (WGS). Click either name above to swap in a different company.

GeneDx Holdings Corp. is the larger business by last-quarter revenue ($121.0M vs $71.0M, roughly 1.7× Cheer Holding, Inc.). Cheer Holding, Inc. runs the higher net margin — 10.9% vs -14.6%, a 25.5% gap on every dollar of revenue. On growth, GeneDx Holdings Corp. posted the faster year-over-year revenue change (26.5% vs -0.1%).

Cheer Holding, Inc. is a diversified holding company primarily operating in the Chinese market, with core business segments covering early childhood education services, mobile lifestyle platforms, digital content offerings, and integrated consumer solutions for households and enterprise partners across multiple demand scenarios.

GeneDx is a genetic testing company that was founded in 2000 by two scientists from the National Institutes of Health (NIH), Sherri Bale and John Compton. They started the company to provide clinical diagnostic services for patients and families with rare and ultra-rare disorders, for which no such commercial testing was available at the time. The company started in the Technology Development Center, a biotech incubator supported by the state of Maryland and Montgomery County, MD. In 2006, Bi...

CHR vs WGS — Head-to-Head

Bigger by revenue
WGS
WGS
1.7× larger
WGS
$121.0M
$71.0M
CHR
Growing faster (revenue YoY)
WGS
WGS
+26.6% gap
WGS
26.5%
-0.1%
CHR
Higher net margin
CHR
CHR
25.5% more per $
CHR
10.9%
-14.6%
WGS

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
CHR
CHR
WGS
WGS
Revenue
$71.0M
$121.0M
Net Profit
$7.8M
$-17.7M
Gross Margin
70.7%
69.6%
Operating Margin
11.7%
-11.8%
Net Margin
10.9%
-14.6%
Revenue YoY
-0.1%
26.5%
Net Profit YoY
-37.5%
-424.9%
EPS (diluted)
$0.67
$-0.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHR
CHR
WGS
WGS
Q4 25
$121.0M
Q3 25
$116.7M
Q2 25
$71.0M
$102.7M
Q1 25
$87.1M
Q4 24
$95.6M
Q3 24
$76.9M
Q2 24
$71.1M
$70.5M
Q1 24
$62.4M
Net Profit
CHR
CHR
WGS
WGS
Q4 25
$-17.7M
Q3 25
$-7.6M
Q2 25
$7.8M
$10.8M
Q1 25
$-6.5M
Q4 24
$5.4M
Q3 24
$-8.3M
Q2 24
$12.4M
$-29.2M
Q1 24
$-20.2M
Gross Margin
CHR
CHR
WGS
WGS
Q4 25
69.6%
Q3 25
72.4%
Q2 25
70.7%
69.0%
Q1 25
67.1%
Q4 24
69.2%
Q3 24
62.2%
Q2 24
73.4%
60.9%
Q1 24
59.9%
Operating Margin
CHR
CHR
WGS
WGS
Q4 25
-11.8%
Q3 25
-2.8%
Q2 25
11.7%
8.7%
Q1 25
-5.2%
Q4 24
9.2%
Q3 24
-10.1%
Q2 24
16.4%
-15.0%
Q1 24
-21.9%
Net Margin
CHR
CHR
WGS
WGS
Q4 25
-14.6%
Q3 25
-6.5%
Q2 25
10.9%
10.5%
Q1 25
-7.5%
Q4 24
5.7%
Q3 24
-10.8%
Q2 24
17.5%
-41.4%
Q1 24
-32.4%
EPS (diluted)
CHR
CHR
WGS
WGS
Q4 25
$-0.59
Q3 25
$-0.27
Q2 25
$0.67
$0.36
Q1 25
$-0.23
Q4 24
$0.25
Q3 24
$-0.31
Q2 24
$1.23
$-1.10
Q1 24
$-0.78

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHR
CHR
WGS
WGS
Cash + ST InvestmentsLiquidity on hand
$171.3M
Total DebtLower is stronger
$54.5M
Stockholders' EquityBook value
$322.1M
$308.2M
Total Assets
$362.7M
$523.7M
Debt / EquityLower = less leverage
0.18×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHR
CHR
WGS
WGS
Q4 25
$171.3M
Q3 25
$155.1M
Q2 25
$134.6M
Q1 25
$159.2M
Q4 24
$141.2M
Q3 24
$116.5M
Q2 24
$186.1M
$106.9M
Q1 24
$112.9M
Total Debt
CHR
CHR
WGS
WGS
Q4 25
$54.5M
Q3 25
$54.8M
Q2 25
$55.1M
Q1 25
$55.5M
Q4 24
$55.8M
Q3 24
$56.1M
Q2 24
$56.3M
Q1 24
$56.3M
Stockholders' Equity
CHR
CHR
WGS
WGS
Q4 25
$308.2M
Q3 25
$292.3M
Q2 25
$322.1M
$277.1M
Q1 25
$257.4M
Q4 24
$245.2M
Q3 24
$204.5M
Q2 24
$286.1M
$194.0M
Q1 24
$207.2M
Total Assets
CHR
CHR
WGS
WGS
Q4 25
$523.7M
Q3 25
$493.9M
Q2 25
$362.7M
$463.9M
Q1 25
$446.4M
Q4 24
$419.4M
Q3 24
$408.8M
Q2 24
$333.2M
$389.1M
Q1 24
$394.5M
Debt / Equity
CHR
CHR
WGS
WGS
Q4 25
0.18×
Q3 25
0.19×
Q2 25
0.20×
Q1 25
0.22×
Q4 24
0.23×
Q3 24
0.27×
Q2 24
0.29×
Q1 24
0.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHR
CHR
WGS
WGS
Operating Cash FlowLast quarter
$3.9M
$-3.1M
Free Cash FlowOCF − Capex
$-7.4M
FCF MarginFCF / Revenue
-6.1%
Capex IntensityCapex / Revenue
3.6%
Cash ConversionOCF / Net Profit
0.51×
TTM Free Cash FlowTrailing 4 quarters
$14.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHR
CHR
WGS
WGS
Q4 25
$-3.1M
Q3 25
$15.8M
Q2 25
$3.9M
$10.4M
Q1 25
$10.2M
Q4 24
$-3.2M
Q3 24
$-4.4M
Q2 24
$-6.7M
$-4.5M
Q1 24
$-16.4M
Free Cash Flow
CHR
CHR
WGS
WGS
Q4 25
$-7.4M
Q3 25
$9.6M
Q2 25
$8.1M
Q1 25
$4.1M
Q4 24
$-6.2M
Q3 24
$-5.0M
Q2 24
$-5.9M
Q1 24
$-16.9M
FCF Margin
CHR
CHR
WGS
WGS
Q4 25
-6.1%
Q3 25
8.2%
Q2 25
7.8%
Q1 25
4.7%
Q4 24
-6.5%
Q3 24
-6.6%
Q2 24
-8.3%
Q1 24
-27.0%
Capex Intensity
CHR
CHR
WGS
WGS
Q4 25
3.6%
Q3 25
5.3%
Q2 25
2.3%
Q1 25
7.0%
Q4 24
3.2%
Q3 24
0.8%
Q2 24
1.9%
Q1 24
0.7%
Cash Conversion
CHR
CHR
WGS
WGS
Q4 25
Q3 25
Q2 25
0.51×
0.96×
Q1 25
Q4 24
-0.59×
Q3 24
Q2 24
-0.54×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CHR
CHR

Segment breakdown not available.

WGS
WGS

Diagnostic Test Third Party Insurance$101.1M84%
Diagnostic Test Institutional Customers$15.5M13%
Other$3.4M3%

Related Comparisons